Back to Search Start Over

Memory Pharmaceuticals starts dosing in trial of calcium channel blocker in bipolar disorder

Source :
Health & Medicine Week. October 2, 2006, p189.
Publication Year :
2006

Abstract

Memory Pharmaceuticals Corp. (MEMY) announced the dosing of the first subject in a phase 2a trial of MEM 1003 in patients with acute mania in bipolar disorder. The company is [...]

Details

Language :
English
ISSN :
15316459
Database :
Gale General OneFile
Journal :
Health & Medicine Week
Publication Type :
News
Accession number :
edsgcl.212299056